info icon

This is a non-core endpoint: only basic statistics are computed.

See these related core endpoints for full statistics:

Non-small cell lung cancer, adenocarcinoma

HLP_C3_NSCLC_ADENO

No definition available.

Endpoint definition

FinnGen phenotype data

429209 individuals

diagram downward connector

Apply sex-specific rule None

429209

diagram downward connector

Check conditions None

429209

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Cause of death: ICD-10 C34.02&, C34.12&, C34.22&, C34.32&, C34.82&, C34.92&
Cancer registry: Topography ICD-O-3 C34
Cancer registry: Morphology ICD-O-3 8140
Cancer registry: Behaviour codes 3

2 out of 7 registries used, show all original rules.

1653

diagram downward connector

Check minimum number of events None

1653

diagram downward connector

Include endpoints None

1653

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

1590

diagram downward connector
HLP_C3_NSCLC_ADENO

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy C
First used in FinnGen datafreeze DF8

Similar endpoints

List of similar endpoints to Non-small cell lung cancer, adenocarcinoma based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 1590 542 1048
Unadjusted prevalence (%) 0.39 0.24 0.58
Mean age at first event (years) 69.49 67.62 70.45

Mortality

Not a core endpoint, no data to show.

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Not a core endpoint, no data to show.

Correlations

Index endpoint: HLP_C3_NSCLC_ADENO – Non-small cell lung cancer, adenocarcinoma
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Non-small cell lung cancer, adenocarcinoma

Endpoint not on priority list, no data to show.